Induction chemotherapy (CT) with FOLFIRINOX or FOLFOX/FOLFIRI, plus cetuximab (CET) or bevacizumab (BEV) (by RAS status), in patients (pts) with primarily unresectable colorectal liver metastases (CRLM): Results of the randomized UNICANCER PRODIGE 14-ACCORD 21 (METHEP-2) trial

Marc Ychou; Michel Rivoire; Simon Thezenas; Rosine Guimbaud; Francois Ghiringhelli; Anne Mercier Blas; Laurent Mineur; Eric Francois; Faiza Khemissa; Marion Chauvenet; Yves Bécouarn; Philippe Houyau; Thomas Aparicio; Marie Pierre Galais; Franck Audemar; Eric Assenat; Antoine Adenis; Claire Jouffroy-Zeller; Rene Adam; Olivier Bouche

doi:10.1200/JCO.2018.36.15_suppl.3535

Retour

Induction chemotherapy (CT) with FOLFIRINOX or FOLFOX/FOLFIRI, plus cetuximab (CET) or bevacizumab (BEV) (by RAS status), in patients (pts) with primarily unresectable colorectal liver metastases (CRLM): Results of the randomized UNICANCER PRODIGE 14-ACCORD 21 (METHEP-2) trial

Article de revue

Avec comité de lecture

Induction chemotherapy (CT) with FOLFIRINOX or FOLFOX/FOLFIRI, plus cetuximab (CET) or bevacizumab (BEV) (by RAS status), in patients (pts) with primarily unresectable colorectal liver metastases (CRLM): Results of the randomized UNICANCER PRODIGE 14-ACCORD 21 (METHEP-2) trial

Marc Ychou, Michel Rivoire, Simon Thezenas, Rosine Guimbaud, Francois Ghiringhelli, Anne Mercier Blas, Laurent Mineur, Eric Francois, Faiza Khemissa, Marion Chauvenet, …

Journal of clinical oncology, Vol.36(15_suppl), pp.3535-3535

20/05/2018

DOI: https://doi.org/10.1200/JCO.2018.36.15_suppl.3535

Résumé

Abstract only

Indicateurs

1 Consultations de la notice

Détails

Titre: Induction chemotherapy (CT) with FOLFIRINOX or FOLFOX/FOLFIRI, plus cetuximab (CET) or bevacizumab (BEV) (by RAS status), in patients (pts) with primarily unresectable colorectal liver metastases (CRLM): Results of the randomized UNICANCER PRODIGE 14-ACCORD 21 (METHEP-2) trial
Créateurs - sans rôle: Marc Ychou - Institut du Cancer de Montpellier (ICM), Univ Montpellier, Montpellier, France
Michel Rivoire - Centre Léon Bérard
Simon Thezenas - Institut du Cancer de Montpellier (ICM), Univ Montpellier, Montpellier, France
Rosine Guimbaud - Centre Hospitalier Rangueil, Toulouse, France
Francois Ghiringhelli - Centre Georges François Leclerc
Anne Mercier Blas - Centre Hospitalier Privé de Saint-Grégoire, Saint-Gregoire, France
Laurent Mineur - Institut Sainte Catherine
Eric Francois - Centre Antoine Lacassagne
Faiza Khemissa - CH Saint Jean, Perpignan, France
Marion Chauvenet - Centre Hospitalier Lyon Sud, Pierre Benite, France
Yves Bécouarn - Bergonié Institute, Bordeaux, France
Philippe Houyau - Clinique Claude Bernard, Albi, France
Thomas Aparicio - Assistance Publique – Hôpitaux de Paris
Marie Pierre Galais - Centre François Baclesse, Caen, France
Franck Audemar - Centre hospitalier Côte Basque, Bayonne, France
Eric Assenat - Hôpital Saint Eloi
Antoine Adenis - Institut du Cancer de Montpellier (ICM), Univ Montpellier, Montpellier, France
Claire Jouffroy-Zeller - Unicancer, Paris, France
Rene Adam - Paul Brousse Hospital, France, Villejuif, France
Olivier Bouche - Centre Hospitalier Universitaire de Reims
Détails de publication: Journal of clinical oncology, Vol.36(15_suppl), pp.3535-3535
Identifiants: 99139804309311
Unité académique: Institut de Recherche en Cancérologie de Montpellier - IRCM; Institut de Génétique Moléculaire de Montpellier - IGMM
Langue: English
Type de ressource: Journal article